On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Revenue Growth, Debt Conversion Boost Pressure BioSciences’ (PBIO) Outlook at Close of First Quarter

  • High-pressure lab equipment maker reports ninth consecutive quarter of revenue growth (Y/Y)
  • About 92 percent of debenture debt converted to preferred stock, with aim of uplisting to national stock exchange
  • Patented technologies continue to drive optimism for company’s products to enhance and improve scientific research

Pressure BioSciences, Inc. (OTCQB: PBIO), the maker of a patented and powerful line of pressure-based scientific laboratory tools, celebrated corporate gains on May 15 with the announcement of first quarter revenue growth and debenture conversion.

The first quarter of 2018 was the ninth consecutive quarter in which the company reported an increase in products and services revenue on a year-over-year basis and the second time during the past year in which the company reported total quarterly revenue of more than $600,000. Sales of the company’s instruments established a new quarterly record, and sales of the instruments’ consumable elements increased by 18 percent following on a 21 percent revenue increase for the final quarter of 2017.

In addition to the revenue achievements, the company reported that, operationally, it was advancing in its relationships with clients as a new cadre of sales directors began working in their assigned geographical areas.

“Perhaps most exciting was the news released just today – that a majority of our 2015/2016 Convertible Debenture Holders have agreed to convert approximately $6.39M of Debentures into Series AA Preferred Stock,” CEO and President Richard T. Schumacher stated in a news release. “This represents about 92% of all 2015/2016 Debenture debt on our balance sheet as of March 31, 2018.”

Schumacher reported that discussions are ongoing with other debt holders about converting their notes into equity, which would give the company a “materially stronger” balance sheet at the end of the second quarter.

“We believe that such a change would have a significant, positive effect on the growth of PBI going forward, and would materially enhance our stated objective of up-listing to a national exchange (NASDAQ, NYSE/Amex) later in 2018,” Schumacher stated.

Pressure BioSciences is focused on the development and sale of instruments and consumables that use high pressures to break open cells in a more efficient, beneficial and reproducible way than today’s standard methods, such as mechanically “beating up” cells amid research aimed at developing medicinal and therapeutic products. The high-pressure products can also be used in counter-terrorism and criminal forensics applications.

The company’s products employ the properties of both constant (static) and alternating (cycling) hydrostatic pressure. The company’s patented pressure cycling technology (PCT) uses alternating cycles between ambient and ultra-high pressures to control biomolecular interactions in a reproducible way that allows for standards compliance reporting to government agencies.

“Because it is so powerful, unique, and enabling, Pressure Cycling Technology (PCT) could play a crucial role for the new generation of discoveries yet to be made. By carefully controlling the breakage of a cell in order to safely and reproducibly release the proteins, lipids, DNA and RNA contained inside the cell, the molecules released have been reported by numerous authors to be of greater quality, which importantly could result in newer, faster, and better discoveries,” Schumacher said in a January interview (http://ibn.fm/7Jjrp).

One of Pressure BioSciences’ newest clients is a company using a patented technology platform acquired as part of Pressure BioSciences’ recent purchase of Colorado-based therapeutic drug developer BaroFold, Inc., a company Schumacher described as available at a bargain price after it “ran into some (operational) problems” that he believes Pressure BioSciences can overcome at relatively low cost. The acquisition gave Pressure BioSciences eight new pressure-related patents and extended the potential for the company’s existing patents.

This newly acquired technology platform, called PreEMT, also holds the promise that a protein drug maker might someday decide to use the company’s PreEMT technology platform in the routine manufacture of its drug to make a higher quality therapeutic, which in turn could result in the drug maker paying a hefty royalty license fee to PBI – perhaps in the millions of dollars per year. “The BaroFold technology platform offers a cutting-edge method to increase the quality and reduce the cost of manufacturing protein drugs. We’ve opened up a whole new and exciting business unit for PBI and our shareholders, one that offers the potential to generate millions of dollars in revenue, per year”, Schumacher said earlier this year.

The company also announced a co-marketing and distribution agreement with ISS, Inc., for high-pressure optical cell systems used in some lab processes. The two-year agreement will include replacing the manual pressure generator used in ISS’s product with Pressure BioSciences’ computer-controlled instruments.

For more information, visit the company’s website at www.PressureBioSciences.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Archives

Select A Month
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered